I am an MS [multiple sclerosis] patient and I have just about had it with my Rebif injections. I've heard about a new leukemia drug used to treat the beginning stages of MS. I think it's called Campath 1H. Are there any other medications you would recommend for early stage MS? Thank you.
Shares of Abbott Laboratories stabilized Tuesday after dropping more than 2% in the previous session when it said it would buy the industry's biggest Lasik vision equipment maker for $2.8 billion.
On the site of a former amusement park in a small Pennsylvania town, technicians sheathed in plastic suits labor over stainless steel fermentation tanks that look like brewery vats.
Big Pharma companies Pfizer, Lilly and Wyeth beat analysts' expectations Thursday with reports of strong gains in third-quarter earnings, though Pfizer isn't expecting annual profit growth until 2009 and is ramping up its already ambitious cost-cutting efforts.
I am an MS [multiple sclerosis] patient and I have just about had it with my Rebif injections. I've heard about a new leukemia drug used to treat the beginning stages of MS. I think it's called Campath 1H. Are there any other medications you would recommend for early stage MS? Thank you.
Shares of Abbott Laboratories stabilized Tuesday after dropping more than 2% in the previous session when it said it would buy the industry's biggest Lasik vision equipment maker for $2.8 billion.
On the site of a former amusement park in a small Pennsylvania town, technicians sheathed in plastic suits labor over stainless steel fermentation tanks that look like brewery vats.
Big Pharma companies Pfizer, Lilly and Wyeth beat analysts' expectations Thursday with reports of strong gains in third-quarter earnings, though Pfizer isn't expecting annual profit growth until 2009 and is ramping up its already ambitious cost-cutting efforts.
Abbott Labs' fast-growing flagship drug Humira is grabbing market share and making money ... and now the company is trying to win the blessings of the FDA to make more.
A federal jury ruled that Eli Lilly & Co. infringed the patent of Ariad Pharmaceuticals with its drugs Evista and Xigris, and ordered the drugmaker to pay the Massachusetts biotech firm $65.2 million, the companies said.
Drug sales, bolstered by Medicare coverage, are projected to keep rising for the next 10 years, and biotechs are expected to get the lion's share of that increase, while the more traditional Big Pharma companies get squeezed by generic drug makers.
Bristol-Myers Squibb faces votes by FDA advisory panels on two key drugs in its pipeline, decisions that could affect the company's financial future for years to come.
Scientists using nanotechnology have devised a way of delivering cancer drugs that could make them up to 10 times more effective in combating the killer disease.
The black box label is the most potent warning in the Food and Drug Administration's arsenal, but it is not necessarily a death knell for drug sales, analysts say.
A cannabis-based painkiller for sufferers of multiple sclerosis is expected to be in Canadian pharmacies this summer, but whether it appears on U.S. pharmacy shelves is a key question.
Two drug candidates that would reduce the symptoms of rheumatoid arthritis have passed testing, announced drug manufacturers Human Genome Sciences, Roche, Genentech and Biogen Idec on Wednesday, offering hope where arthritis treatments have raised health concerns.
Johnson & Johnson says its rheumatoid arthritis drug Remicade may put patients at higher risk for lymphoma, and the company is sending out warning letters to physicians.
A common thread connects this year's standouts: They all responded to crisis by radically changing the way they make things. Autoliv reprocessed its factory to fend off stiff competition in airbags...
The Empire State ballroom at the Grand Hyatt Hotel in midtown Manhattan typically serves as the setting for the kind of stuffy, state-of-a-business luncheons that are more snooze inducing than buzz...
Nokia's disappointing sales announcement and the resulting fallout in the tech sector makes a lot of nervous investors even jumpier. In particular, they fear that any earnings disappointments during the next few weeks may lead to sudden selloffs.
Scientist Eugene Sun remembers exactly how his boss at Abbott Laboratories responded some years ago to Sun's report on his breakthrough AIDS drug, Kaletra: "I'm tired of hearing about science, I wa...
For years Amgen has seemed biotechnology's best answer to the likes of Merck--a sector leader with so much heft and momentum that you'd recommend its stock to your mom. But now making that analogy ...
Patients who want the rheumatoid arthritis-fighting drug Enbrel have to show a special card to their pharmacist, who then verifies that the patient is enrolled in the Enbrel program before dispensi...
Like any good family practitioner, Dr. Reginald Parker believes in protecting against loss. So he begins his financial exams with some basic questions: What stocks do the mutual funds own? What ind...
The page you requested cannot be found. The page you are looking for might have been removed, had its name changed, or is temporarily unavailable.
Please try the following:
• If you typed the page address in the Address bar, make sure that it is spelled correctly.
• Open the www.cnn.com home page and look for links to the information you want.
• Use the navigation bar above to find the link you are looking for.
• Click the Back button to try another link.
• Enter a term in the search form below to look for information on CNN sites or the Internet.
Video
